Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes (T2D): Outcomes by Body Mass Index (BMI)

被引：0
|
作者：
Shatskov, Alla
Rezvani, Geoffrey
Mansfield, Traci
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1141-P
引用
收藏
页码：A299 / A299
页数：1
相关论文
共 50 条
  • [1] Dapagliflozin (DAPA) in Patients with Type 2 Diabetes (T2D) and Mixed Dyslipidemia
    Bays, Harold E.
    Sartipy, Peter
    Xu, John
    Langkilde, Anna Maria
    Sjostrom, C. David
    DIABETES, 2016, 65 : A306 - A306
  • [2] Efficacy and Safety of Ipragliflozin (IPRA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by Body Mass Index (BMI)
    Kashiwagi, Atsunori
    Yoshida, Satoshi
    Nakamura, Ichiro
    Kazuta, Kenichi
    Ueyama, Eiji
    Takahashi, Hideyuki
    Satomi, Hayato
    Kosakai, Yoshinori
    Kawamuki, Kousei
    DIABETES, 2015, 64 : A309 - A309
  • [3] Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D)
    Ang, Lynn
    Kidwell, Kelley M.
    Dillon, Brendan
    Reiss, Jacob
    Fang, Fang
    Leone, Virginia
    Mizokami-Stout, Kara
    Pop-Busui, Rodica
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (08)
  • [4] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes: Outcomes by Race and Ethnicity
    Moran, Jason
    Yeh, Helen
    Katz, Arie
    DIABETES, 2015, 64 : A315 - A315
  • [5] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Sawhney, Sangeeta
    Banks, Phillip L.
    Jiang, Wenjun
    Lapuerta, Pablo
    DIABETES, 2020, 69
  • [6] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Lapuerta, Pablo
    Banks, Phillip L.
    Jiang, Wenjun
    Sawhney, Sangeeta
    DIABETES, 2020, 69
  • [7] Quality Measure Outcomes with Dapagliflozin (DAPA) Add-on to Metformin (MET) or Insulin (INS) in Patients with Type 2 Diabetes (T2D)
    Mansfield, Traci
    Bell, Kelly
    Rezvani, Geoffrey
    Shatskov, Alla
    Sheehan, John J.
    DIABETES, 2016, 65 : A307 - A307
  • [8] Efficacy and safety of dapagliflozin in type 1 diabetes according to baseline body mass index: pooled outcomes from the DEPICT-1 and-2 studies
    Dandona, P.
    Mathieu, C.
    Phillip, M.
    Scheerer, M. F.
    Xu, J.
    Thoren, F.
    Iqbal, N.
    DIABETOLOGIA, 2019, 62 : S345 - S346
  • [9] Gene Expression and Metformin Efficacy in Type 2 Diabetes (T2D)
    Prudente, Sabrina
    Masotti, Andrea
    Copetti, Massimiliano
    Caporarello, Nunzia
    Proto, Vittoria
    Da Sacco, Letizia
    Morini, Eleonora
    Mercuri, Luana
    Bailetti, Diego
    Palena, Antonio
    Baratta, Roberto
    De Cosmo, Salvatore
    Pellegrini, Fabio
    Ludovico, Ornella
    Frittitta, Lucia
    Trischitta, Vincenzo
    DIABETES, 2013, 62 : A430 - A430
  • [10] Genital infections and relation to body mass index in patients with type 2 diabetes mellitus treated with dapagliflozin
    Rudofsky, G.
    Baldycheva, I.
    Johnsson, E.
    Rohwedder, K.
    DIABETOLOGIA, 2015, 58 : S365 - S365
12345